Credits: iStock
Flu season has meant rolling up your sleeve for a shot at the doctor’s office or pharmacy. Now, that’s changing. AstraZeneca has launched FluMist Home, the first FDA-approved flu vaccine that can be delivered to your doorstep and self-administered—no needles required.
This new option, a nasal spray version of the vaccine, builds on FluMist’s two-decade track record. First approved by the Food and Drug Administration (FDA) in 2003, FluMist has long been available at clinics and pharmacies. But in September 2024, the FDA gave the green light for at-home self-administration. Less than a year later, the program is rolling out across 34 states in time for the 2025–2026 flu season.
The stakes couldn’t be higher, last flu season was one of the most severe in recent memory. The CDC estimates up to 82 million illnesses, 1.3 million hospitalizations, and 130,000 deaths from flu between October 2024 and May 2025. Yet vaccination rates remained low, with fewer than half of Americans getting their annual shot.
Experts say that convenience is a major barrier. Between busy schedules, limited access to clinics, and vaccine hesitancy, too many people skip protection. FluMist Home could remove at least one of those hurdles by making the process as simple as ordering online.
“People are increasingly comfortable with managing their health at home—whether through Covid-19 tests or self-injections for chronic conditions,” explains AstraZeneca. “This option takes advantage of that shift and expands access to flu vaccination.”
FluMist Home is FDA-approved for people ages 2 through 49. Adults can use it themselves, while children as young as 2 can receive it with help from a parent or caregiver.
However, it’s not for everyone. Because FluMist is a live, weakened-virus vaccine, pregnant women and people with weakened immune systems should consult their doctors before considering it. Those outside the approved age range must still rely on traditional flu shots.
The ordering process mirrors a telehealth experience. Patients complete a brief medical questionnaire online, which is reviewed by a licensed healthcare provider before the prescription is approved. Insurance covers the cost for most users, with a flat $8.99 shipping and handling fee.
When FluMist arrives, it’s shipped in insulated, temperature-controlled packaging with ice packs to preserve stability. Each vial contains two pre-measured doses one for each nostril—separated by a clip. To administer, simply breathe normally while spraying; there’s no need to inhale deeply. A slight tickle, sneeze, or drip afterward is normal.
Patients can download a vaccination record from the online portal, and—if permission is given—the record is automatically shared with their doctor and uploaded to state vaccine registries.
AstraZeneca emphasizes that FluMist Home uses the same formulation and vial as the version given in clinics. Its efficacy is on par with injectable flu vaccines, but the delivery method is needle-free.
The most common side effects are mild: runny nose, nasal congestion, and sore throat in adults. Children may experience low-grade fever. These symptoms generally resolve quickly.
Importantly, the FDA required AstraZeneca to conduct a usability study before approval. Results showed that 100% of participants were able to correctly self-administer the full dose without healthcare supervision.
Needle-free, self-administered vaccines aren’t just about convenience—they may be critical in improving uptake. FluMist Home joins a growing trend of decentralizing preventive healthcare, putting tools directly into patients’ hands.
Historically, nasal spray flu vaccines were popular among children and adults who disliked shots. Now, offering a home option could further broaden access. As public health experts warn about the dangers of simultaneous flu, RSV, and Covid-19 waves, innovations like FluMist Home might play a pivotal role in reducing strain on hospitals.
The CDC notes that every additional percentage point increase in vaccination coverage can save thousands of lives during peak flu seasons. By lowering logistical barriers, FluMist Home could help close that gap.
The differences between FluMist and injectable vaccines come down to technology. Traditional flu shots use either killed viruses or specific proteins to teach the immune system how to respond. FluMist, by contrast, uses a live but weakened influenza virus. Both methods are proven to work, but some patients respond better to one than the other.
For people who avoid shots due to fear or discomfort, FluMist offers a gentler alternative. For children, especially, a quick nasal spray can mean less stress and higher compliance.
The rollout of FluMist Home may be a harbinger of bigger changes. The pandemic normalized home-based care and accelerated acceptance of mail-order biologics, self-testing kits, and virtual consultations. Vaccines, once the exclusive domain of clinics, could follow suit.
Some researchers are already working on shelf-stable, oral, or patch-based vaccines that could one day make prevention even more accessible. For now, FluMist Home represents a significant step forward in modernizing how people protect themselves during flu season.
Timing: Administer early in flu season for maximum protection.
Recordkeeping: Save your vaccination confirmation for medical records and travel purposes.
Disposal: Packaging materials are largely recyclable; chill packs can be reused.
FluMist Home gives people a practical, needle-free, at-home option to stay protected against the flu. While it’s not suitable for everyone, its convenience could boost vaccination rates at a time when respiratory viruses remain a major public health threat.
Credits: Canva
By now, most of us know the liver as the tireless detox unit of the body. It takes in the grease, sugar, alcohol, and all the questionable late-night binge decisions and keeps life moving smoothly. But when the liver is badly scarred by cirrhosis, the consequences are not just digestive. According to Dr Joseph Salhab, a gastroenterologist, it can creep up and affect your brain in a condition known as overt hepatic encephalopathy (OHE). And trust us, the symptoms can be stranger than ever.
Yes, and it is not even funny. "OHE is a complication of cirrhosis and occurs when the liver sustains damage and loses its ability to remove toxins from the bloodstream effectively, causing toxins to accumulate and lead to impaired brain function," explains Dr Salhab.
The results in symptoms that do not immediately lead to liver problems. People may develop personality changes, tremors, disorientation, or even a complete shift in their sleep-wake cycles. Imagine feeling jetlagged without ever stepping on a plane.
Also Read: Why Your Anxiety Might Be In Your DNA: Study
Dr Salhab stresses that OHE often goes undetected because its symptoms can look like other issues—stress, ageing, or even just a bad week. Confusion, forgetfulness, mood swings, and sudden changes in behaviour are all warning signs that should not be ignored. Families sometimes notice it first, especially when a usually calm person turns irritable or when handwriting suddenly looks shaky and uneven.
Tremors and clumsiness are another giveaway. These motor symptoms are particularly telling because they show the brain is being affected in very real ways.
It is this toxin overload that leads to the neurological and psychological effects we see in OHE. This makes OHE not just a medical problem but a quality-of-life bombshell.
Left unchecked, OHE episodes can become severe, even leading to hospitalisation. Patients might not recognise loved ones, forget basic routines, or lose the ability to care for themselves. The impact is not just medical but social and emotional. It affects families, careers, and independence.
In fact, many carers share stories of how they mistook early OHE signs for dementia or burnout. It is only after medical consultation that the link between liver and brain became clear.
Also Read: How Neoadjuvant Therapy Changes The Game In Breast Cancer Treatment
The good news is yes, but it requires vigilance. The first step is awareness. Knowing that cirrhosis can lead to OHE empowers patients and families to act early. Regular check-ups, honest conversations with doctors, and close monitoring of symptoms are essential in staying ahead of episodes.
Lifestyle choices also make a difference. Following medical advice on diet, avoiding alcohol, and keeping other health issues like diabetes under control can all reduce the strain on the liver.
One of the biggest obstacles is silence. People usually do not report symptoms like confusion or mood swings because they do not connect them to their liver condition. But being open about every change, no matter how small, helps doctors spot OHE early.
Even something as simple as poor sleep or hand tremors can be clues your doctor needs. Despite sounding like a rare complication, OHE is more common than most realise. Cirrhosis itself is a growing health issue, linked not only to alcohol but also to obesity and viral hepatitis. As cirrhosis rates rise, awareness about OHE has to grow too.
If you or someone you love has cirrhosis, those little signs like irritability, shaking hands, or sudden confusion might not just be signs. They could be OHE waving its red flag. And the earlier it is caught, the better the chances of managing it.
Credits: Canva
Vax-Before-Travel, an international publisher of vaccine information noted that in 2025 Lyme disease ticks have progressed westward into many midwestern states. It has also reported a significant increase. However, while the Tick Season is back, there is a new Lyme treatment on the horizon. But, with it, there are also unique symptoms that one has to be aware of.
The ongoing threat of ticks is usual when one is enjoying their time as the weather warms up. They can be found in your backyard and can transmit Lyme disease, a tickborne infection caused by the bacteria Borrelia burgdorferi.
While Lyme disease is usually resolved with a short course of antibiotics, it is not always a simple illness. Sometimes, it can lead to prolonged symptoms, if untreated.
As per American Medical Association (AMA), Lyme disease is the most common vector-borne disease in the US, with an estimated 476,000 people diagnosed and treated each year. The numbers are also corroborated with the Centers for Disease Control and Prevention (CDC).
The Maryland Government Health website also notes that for about 75% of those diagnosed with Lyme disease, the first sign is always a skin lesion. This appears within one to four weeks after being bitten by an infected deer tick. However, only about 20% of these lesions take on the classic bull's eye appearance, which is most commonly associated with Lyme disease. This means, 55% of those with lesions may not even be diagnosed with the condition, and may not get the treatment.
ALSO READ: Lyme Disease In US: How Worried Should You Be Of Ticks?
The Time reports that if Lyme is not treated early on, it can impact the cardiac, neurologic, and rheumatologic systems. The CDC notes that 1 out of 100 patients have Lyme bacteria in their heart tissues. The condition is also called Lyme carditis.
This leads to heart inflammation, light headedness, fainting, shortness of breath, heart palpitations, or chest pain.
John Hopkins Medicine Lyme Disease Research Center notes that advanced brain imaging shows that Lyme disease brain fog is real. It can lead to various brain effects, including difficulty in focusing, thinking, reading, and absorbing information.
There are 12 essential nerves, also known as the cranial nerves that originate in the brain and play an important role in sensory functions and movements in the different parts of the head, face, neck, and torso. Lyme disease can also affect those nerves, leading to Bell's Palsy, causing sudden weakness or even paralysis.
Some people may experience eye irritation and conjunctivitis. The American Journal of Medicine's 1995 study also suggests that Lyme can cause sudden vision loss, damage to optic nerve, and neurotrophic keratitis (decreased corneal sensation). Other symptoms include blurry vision, eye floaters, tearing and extreme sensitivity to light.
A 2018 study published in Otolaryngologia Polska, reported of the 216 people with tickborne disease, 162 experienced otolaryngological symptoms—making them a “frequent manifestation,” according to the study authors. The most common hearing issues are tinnitus, vertigo and dizziness, headache, and unilateral sensorineural hearing or hearing loss in one ear.
It is one of the common symptoms of Lyme disease, especially in young people. It can be seen in form of a swollen knee, a low grade fever, or a kid limping. It usually starts at a fourth week of being bitten.
On a hopeful note, researchers at Northwestern University in Illinois recently screened over 500 antibiotics and FDA-approved compounds to identify treatments that specifically target the unique cellular makeup of Borrelia burgdorferi, the bacteria behind Lyme disease.
Their findings, published in Science Translational Medicine, revealed that piperacillin, an antibiotic from the penicillin family, successfully cured mice of Lyme disease at doses 100 times lower than doxycycline, the standard treatment currently in use.
This is not just any fatigue, but a weakness that is debilitating. A 2022 study published in the International Journal of Infectious Diseases noted that people with a history of Lyme were 8 to 15 times more likely to report severe or moderate fatigue than those who have never had the disease.
READ: Family Shares How A Lyme Disease Misdiagnosis Cost Their Son's Childhood
As per the National Health Service, (NHS), UK, in case of a rash, it can appear up to 3 months after being bitten by an infected tick. However, in most common cases, it appears within 1 to 4 weeks, and stays for several weeks.
In cases of untreated Lyme disease, the symptoms may appear later, and may become chronic, like debilitating fatigue.
Credits: Canva
Breast cancer has a strange way of being both familiar and frightening. Almost everyone knows someone who has battled it, and yet the details of treatment often sound like an alien language. According to the World Health Organisation, breast cancer is the most common cancer among women worldwide, with 2.3 million new cases in 2022 alone. Among these, about 15 to 20 per cent are HER2-positive, the type that is fast-moving, aggressive, and hard to ignore.
Increasingly, the doctors are turning to a strategy that feels a bit like hitting “pause” before the main act—neoadjuvant therapy.
HER2 (human epidermal growth factor receptor 2) is a protein that helps cells grow. In HER2-positive breast cancer, the cells get an overdose of this protein. As a result, the cancer multiplies faster than usual and is often linked to poorer outcomes.
“HER2-positive breast cancer is an aggressive type,” explains Dr Mandeep Singh Malhotra, co-founder, Art Of Healing Cancer. “It is very important to give the right information to patients and their families for better outcomes. With the right treatment sequence, it is possible to offer better treatment to patients.”
Neoadjuvant therapy (NT) is like a warm-up session but for cancer treatment. Instead of rushing into surgery to remove the tumour, doctors first administer chemotherapy and targeted drugs. The idea is to shrink the tumour, make surgery easier, and gather valuable intel on how the cancer responds.
“Nowadays, when we talk about HER2-positive breast cancer, we talk about targeted therapy and dual targeted therapy involving both trastuzumab and pertuzumab,” says Dr Malhotra. Both are monoclonal antibodies, meaning they are lab-made molecules designed to stick to specific parts of cancer cells. Together with chemotherapy, they not only shrink tumours but also improve surgical outcomes.
One of the superpowers of neoadjuvant therapy is its ability to act as a kind of crystal ball. By giving treatment before surgery, doctors can tell which patients are “responders” and which are not.
“As Dr Malhotra puts it, “Even at early stages, if we give NT and then operate, we are able to prognosticate. Responders have a better prognosis. Non-responders have poorer prognosis and a higher chance of the cancer coming back.”
This ability to sort patients into risk categories allows doctors to tailor follow-up care more precisely. For example, non-responders may be put on more aggressive treatments, offered newer diagnostic tests like liquid biopsy, or monitored more closely.
Surgery-first and neoadjuvant-first have similar survival data, but the latter provides an extra layer of information.
“If we do upfront surgery in these patients, we lose the chance of prognostication,” says Dr Malhotra. “Secondly, even if we do the upfront surgery, we will still have to give chemo with targeted therapy after surgery. So the treatment does not change; the sequence changes. And with neoadjuvant therapy, we get the added benefit of knowing who is high risk and who is low risk.”
In other words, neoadjuvant therapy is not just about shrinking tumours; it is about outsmarting them.
For patients, all of this can feel overwhelming. Surgery often seems like the most direct way to “get rid” of cancer, so the idea of delaying it can cause anxiety. But Dr Malhotra reassures patients that this approach is carefully designed.
“Even in very early-stage breast cancer, with a less than 1 cm tumour, I will not go for surgery first,” he says. “I will first give targeted chemotherapy. The reason is I see a lot of patients who have already had surgery and then are given the option of dual therapy. They are confused and afraid that the cancer will come back if they cannot afford either trastuzumab or pertuzumab.”
Interestingly, cost can also play a role. If patients achieve a complete response, meaning no invasive cancer remains after neoadjuvant therapy, sometimes treatment can be stopped earlier, sparing both physical and financial strain. “We lose this opportunity if surgery is opted for first,” Dr Malhotra adds.
The shift towards neoadjuvant therapy represents a significant change in how doctors approach HER2-positive breast cancer. Instead of rushing in with surgery, the modern strategy is more like a chess game, carefully setting up each move to give patients the best possible outcome.
By combining chemotherapy with targeted drugs like trastuzumab and pertuzumab before surgery, doctors can shrink tumours, assess risk, personalise treatment, and often improve long-term survival.
Breast cancer treatment has always been a mix of science, strategy, and courage. Neoadjuvant therapy, especially in HER2-positive cases, is proving to be more than just a pre-surgery step. It is a game-changer, giving both patients and doctors a crucial edge in the fight.
As Dr Malhotra puts it, “Neoadjuvant therapy is not an inferior modality. With current data, we feel it is a superior one.”
© 2024 Bennett, Coleman & Company Limited